Daunorubicin adverse effects

Adverse effects Irreversible, dose-dependent cardiotoxicity, apparently a result of the generation of free radicals, is the most serious adverse reaction. Irradiation of the thorax increases the risk of cardiotoxicity. There has been some success with the iron chelator, dexrazone, in protecting against the cardiotoxicity of doxorubicin. As with dactinomycin, both doxorubicin and daunorubicin also cause a transient bone marrow suppression, stomatitis, and Gl tract disturbances. Alopecia is usually severe. 

Daunorubicin is primarily used in the treatment of AML in combination with Ara-C and has largely been replaced by idarubicin. The toxic manifestations of daunorubicin as well as idarubicin include bone marrow depression, stomatitis, alopecia, G1 disturbances, and dermatological manifestations. Cardiac toxicity is a peculiar adverse effect observed with these agents. It is characterized by tachycardia, arrhythmias, dyspnea, hypotension, pericardial effusion, and CHF that is poorly responsive to digitalis. 

Pacific Northwest.) Encyclopedic references comment that the antibiotics doxorubicin, daunorubicin, bleomycin, mitomycin, and dactinomycin are all antineoplastic or anticancer agents, but are mostly too toxie for antibiotic use (and perhaps are too toxic to be used as anticancer agents, a ease again of adverse side effects). 

---